Total Payments
$1.0M
2024 Payments
$408.61
Companies
15
Transactions
62
Medicare Patients
14,829
Medicare Billing
$9.7M
Payment Breakdown by Category
Other$1.0M (99.9%)
Food & Beverage$1,132 (0.1%)
Gifts$17.24 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Acquisitions | $756,333 | 2 | 75.1% |
| Current or prospective ownership or investment interest | $249,856 | 9 | 24.8% |
| Food and Beverage | $1,132 | 40 | 0.1% |
| Gift | $17.24 | 1 | 0.0% |
| Unspecified | $0 | 10 | 0.0% |
Payments by Type
General
$1.0M
52 transactions
Ownership
$0
10 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| US Retina LLC | $1.0M | 21 | $0 (2022) |
| Harrow Eye, LLC | $316.36 | 2 | $0 (2024) |
| Genentech USA, Inc. | $204.08 | 12 | $0 (2022) |
| NotalVision | $126.03 | 1 | $0 (2018) |
| Bausch & Lomb, a division of Bausch Health US, LLC | $89.31 | 4 | $0 (2020) |
| Novartis Pharmaceuticals Corporation | $77.80 | 5 | $0 (2020) |
| Allergan Inc. | $74.01 | 4 | $0 (2019) |
| Apellis Pharmaceuticals, Inc. | $43.90 | 2 | $0 (2024) |
| Alimera Sciences, Inc. | $43.24 | 2 | $0 (2024) |
| Mallinckrodt Enterprises LLC | $42.90 | 2 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $408.61 | 6 | Harrow Eye, LLC ($316.36) |
| 2023 | $19.02 | 1 | Apellis Pharmaceuticals, Inc. ($19.02) |
| 2022 | $36,525 | 7 | US Retina LLC ($36,463) |
| 2021 | $735,986 | 8 | US Retina LLC ($735,930) |
| 2020 | $87,604 | 11 | US Retina LLC ($87,478) |
| 2019 | $88,835 | 16 | US Retina LLC ($88,629) |
| 2018 | $57,900 | 7 | US Retina LLC ($57,689) |
| 2017 | $60.51 | 6 | Genentech USA, Inc. ($37.37) |
All Payment Transactions
62 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/11/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $24.51 | General |
| Category: Ophthalmology | ||||||
| 08/17/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $20.24 | General |
| Category: EYE CARE | ||||||
| 07/09/2024 | Harrow Eye, LLC | — | Food and Beverage | In-kind items and services | $167.97 | General |
| 07/08/2024 | Harrow Eye, LLC | — | Food and Beverage | In-kind items and services | $148.39 | General |
| 06/17/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $24.88 | General |
| Category: Ophthalmology | ||||||
| 04/12/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $22.62 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 06/01/2023 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | Cash or cash equivalent | $19.02 | General |
| Category: Ophthalmology | ||||||
| 12/12/2022 | Genentech USA, Inc. | VABYSMO (Drug) | Food and Beverage | In-kind items and services | $20.91 | General |
| Category: Immunology and Ophthalmology | ||||||
| 08/09/2022 | US Retina LLC | — | Acquisitions | Cash or cash equivalent | $28,507.31 | General |
| 07/20/2022 | Genentech USA, Inc. | — | Food and Beverage | In-kind items and services | $19.06 | General |
| 05/18/2022 | Genentech USA, Inc. | Lucentis (Biological), SUSVIMO, VABYSMO | Food and Beverage | In-kind items and services | $21.77 | General |
| Category: Ophthalmology | ||||||
| 04/13/2022 | US Retina LLC | — | Current or prospective ownership or investment interest | Cash or cash equivalent | $6,917.96 | General |
| 04/12/2022 | US Retina LLC | — | Current or prospective ownership or investment interest | Cash or cash equivalent | $1,037.63 | General |
| 2022 | US Retina LLC | — | — | — | $0.00 | Ownership |
| 12/31/2021 | US Retina LLC | — | Acquisitions | Cash or cash equivalent | $727,825.62 | General |
| 07/14/2021 | Genentech USA, Inc. | Lucentis (Biological) | Food and Beverage | In-kind items and services | $19.92 | General |
| Category: Ophthalmology | ||||||
| 05/17/2021 | Regeneron Healthcare Solutions, Inc. | EYLEA (Biological) | Food and Beverage | In-kind items and services | $15.62 | General |
| Category: OPHTHALMOLOGY | ||||||
| 05/11/2021 | US Retina LLC | — | Current or prospective ownership or investment interest | Cash or cash equivalent | $7,037.27 | General |
| 05/06/2021 | US Retina LLC | — | Current or prospective ownership or investment interest | Cash or cash equivalent | $1,067.32 | General |
| 03/04/2021 | Alimera Sciences, Inc. | ILUVIEN (Drug) | Food and Beverage | Cash or cash equivalent | $20.62 | General |
| Category: OPHTHALMOLOGY | ||||||
| 2021 | US Retina LLC | — | — | — | $0.00 | Ownership |
| 2021 | US Retina LLC | — | — | — | $0.00 | Ownership |
| 06/12/2020 | Novartis Pharmaceuticals Corporation | BEOVU (Drug) | Food and Beverage | In-kind items and services | $13.30 | General |
| Category: OPHTHALMOLOGY | ||||||
| 05/11/2020 | Carl Zeiss Meditec, Inc. | None Specified (Medical Supply) | Gift | In-kind items and services | $17.24 | General |
| 03/13/2020 | US Retina LLC | — | Current or prospective ownership or investment interest | Cash or cash equivalent | $85,000.89 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 15 | 3,732 | 12,518 | $10.7M | $2.2M |
| 2022 | 13 | 3,627 | 10,914 | $10.4M | $2.3M |
| 2021 | 14 | 3,368 | 12,634 | $9.9M | $2.6M |
| 2020 | 13 | 4,102 | 13,350 | $10.2M | $2.6M |
Total Patients
14,829
Total Services
49,416
Medicare Billing
$9.7M
Procedure Codes
55
All Medicare Procedures & Services
55 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 222 | 2,176 | $7.0M | $1.5M | 21.3% |
| Q5128 | Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | Office | 2023 | 88 | 1,031 | $866,535 | $222,384 | 25.7% |
| 92014 | Established patient complete exam of visual system | Office | 2023 | 1,057 | 1,968 | $820,636 | $158,528 | 19.3% |
| 67028 | Injection of drug into eye | Office | 2023 | 364 | 1,208 | $849,509 | $106,227 | 12.5% |
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2023 | 22 | 2,580 | $244,558 | $74,828 | 30.6% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2023 | 29 | 347 | $337,590 | $62,543 | 18.5% |
| 92134 | Imaging of retina | Office | 2023 | 884 | 1,962 | $261,907 | $54,401 | 20.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 205 | 205 | $113,115 | $22,167 | 19.6% |
| 92250 | Photography of the retina | Office | 2023 | 689 | 799 | $145,369 | $20,122 | 13.8% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2023 | 85 | 93 | $40,364 | $8,596 | 21.3% |
| 67210 | Destruction of growth of retina using a laser | Office | 2023 | 12 | 14 | $23,499 | $4,797 | 20.4% |
| J9035 | Injection, bevacizumab, 10 mg | Office | 2023 | 25 | 72 | $16,199 | $3,721 | 23.0% |
| 67145 | Photocoagulation treatment to prevent detachment of retina | Office | 2023 | 13 | 14 | $17,668 | $2,249 | 12.7% |
| 92012 | Established patient problem focused exam of visual system | Office | 2023 | 23 | 29 | $8,502 | $1,813 | 21.3% |
| 76512 | 2d ultrasound scan of eye tissue and structures | Office | 2023 | 14 | 20 | $4,360 | $710.43 | 16.3% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2022 | 221 | 2,108 | $6.2M | $1.5M | 23.6% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2022 | 112 | 1,914 | $1.9M | $433,093 | 23.0% |
| 92014 | Established patient complete exam of visual system | Office | 2022 | 1,072 | 2,249 | $834,506 | $182,710 | 21.9% |
| 67028 | Injection of drug into eye | Office | 2022 | 321 | 1,248 | $884,443 | $110,802 | 12.5% |
| 92134 | Imaging of retina | Office | 2022 | 1,048 | 2,385 | $292,148 | $66,402 | 22.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 216 | 216 | $109,333 | $24,054 | 22.0% |
| 92250 | Photography of the retina | Office | 2022 | 418 | 486 | $88,452 | $12,078 | 13.7% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2022 | 111 | 122 | $45,106 | $10,672 | 23.7% |
| 67210 | Destruction of growth of retina using a laser | Office | 2022 | 18 | 26 | $41,881 | $8,877 | 21.2% |
| J9035 | Injection, bevacizumab, 10 mg | Office | 2022 | 30 | 95 | $16,150 | $5,090 | 31.5% |
About Dr. Peter Sonkin, M.D
Dr. Peter Sonkin, M.D is a Ophthalmology healthcare provider based in Nashville, Tennessee. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/26/2006. The National Provider Identifier (NPI) number assigned to this provider is 1003991167.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Peter Sonkin, M.D has received a total of $1.0M in payments from pharmaceutical and medical device companies, with $408.61 received in 2024. These payments were reported across 62 transactions from 15 companies. The most common payment nature is "Acquisitions" ($756,333).
As a Medicare-enrolled provider, Sonkin has provided services to 14,829 Medicare beneficiaries, totaling 49,416 services with total Medicare billing of $9.7M. Data is available for 4 years (2020–2023), covering 55 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Other Specialties Retina Specialist
- Location Nashville, TN
- Active Since 10/26/2006
- Last Updated 09/17/2018
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1003991167
Products in Payments
- Lucentis (Biological) $164.11
- ForeseeHome (Device) $126.03
- OZURDEX (Drug) $94.25
- RETISERT (Drug) $67.39
- BEOVU (Drug) $62.38
- EYLEA (Biological) $44.91
- Syfovre (Drug) $43.90
- ACTHAR (Biological) $42.90
- CLARUS (Device) $24.70
- Izervay (Drug) $24.51
- YUTIQ (Drug) $22.62
- VISUDYNE (Drug) $21.92
- VABYSMO (Drug) $20.91
- ILUVIEN (Drug) $20.62
- None Specified (Medical Supply) $17.24
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Nashville
Dr. Carl Awh, M.d, M.D
Ophthalmology — Payments: $1.3M
Ophthalmology $1.3M
Jeffrey Horn, Md, MD
Ophthalmology — Payments: $516,696
Ophthalmology $516,696
Dr. Eric Schneider, Md, MD
Ophthalmology — Payments: $144,321
Ophthalmology $144,321
David Reichstein, M.d, M.D
Ophthalmology — Payments: $141,351
Ophthalmology $141,351
Akshay Thomas, M.d, M.D
Ophthalmology — Payments: $102,419
Ophthalmology $102,419
Andrew Meador, M.d, M.D
Ophthalmology — Payments: $84,874
Ophthalmology $84,874